Precigen, Inc. (PGEN): Free Cash Flow
-$89.83M
Year ended 2025-12-31
-$115.22M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$89.83M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$76.76M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$68.47M | n/m | 2026-03-25, From 2023-01-01 |
| 2022-12-31 | -$69.97M | n/m | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | -$63.02M | n/m | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | -$84.55M | n/m | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | -$173.81M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$165.83M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$150.39M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$80.62M | n/c | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $22.92M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$26.23M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$55.21M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$69.02M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$94.76M | n/a | 2014-03-31, From 2011-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Precigen, Inc. (PGEN) | 2025-12-31 | -$89.83M | n/m |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | -$83.28M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$172.35M | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$35.0K | n/m |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | -$82.35M | n/m |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | -$72.45M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$758.56M | n/m |
| Jaguar Health, Inc. (JAGX) | 2024-12-31 | -$29.40M | n/a |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.22M | n/m |
Compare PGEN, JANX, ZBIO, ISCO side by side · Screen every company in Pharmaceutical Preparations ↗